{"id":2511,"date":"2026-06-11T17:06:30","date_gmt":"2026-06-11T15:06:30","guid":{"rendered":"https:\/\/path-for-young.unicancer.fr\/?p=2511"},"modified":"2026-07-11T17:24:58","modified_gmt":"2026-07-11T15:24:58","slug":"groundbreaking-optima-study-results-shared-at-asco-personalising-early-breast-cancer-treatment-to-avoid-unnecessary-chemotherapy","status":"publish","type":"post","link":"https:\/\/path-for-young.unicancer.fr\/es-ar\/groundbreaking-optima-study-results-shared-at-asco-personalising-early-breast-cancer-treatment-to-avoid-unnecessary-chemotherapy\/","title":{"rendered":"Groundbreaking OPTIMA Study Results Shared at ASCO: Personalising Early Breast Cancer Treatment to Avoid Unnecessary Chemotherapy"},"content":{"rendered":"<div class=\"plmb plmb-text mce-content clearfix format-intro\">\r\n\t<p data-path-to-node=\"7\">Important results from the OPTIMA study (\u201cOptimal Personalised Treatment of early breast cancer using Multi-parameter Analysis\u201d) were presented at ASCO this weekend by Dr. Robert C. Stein. This UCL-sponsored Phase III trial marks a significant milestone in moving towards more tailored, patient-centric oncological care.<\/p>\n<p data-path-to-node=\"8\">The study demonstrated that many patients aged 40 and over with hormone-sensitive early breast cancer and a low Prosigna score (defined as \u2264 60) can safely avoid chemotherapy. By opting for hormone therapy alone, patients achieved excellent results without compromising their short-term outcomes.<\/p>\n<p data-path-to-node=\"9\">Data from the trial showed that more than two-thirds of participants had a low Prosigna score, with remarkably similar outcomes across groups. Specifically, 94.8% of patients receiving chemotherapy plus hormone therapy were alive and free from recurrence at 5 years, compared with 93.6% of those treated with hormone therapy alone.<\/p>\n<\/div>\r\n\n\n<div class=\"plmb plmb-image image-style-none\">\r\n\t\t<figure>\r\n\t\t<img loading=\"lazy\" decoding=\"async\" width=\"4\" height=\"4\" src=\"https:\/\/path-for-young.unicancer.fr\/wp-content\/uploads\/2026\/07\/1780331305966-e1783782767977.jpeg\" class=\"attachment-fhd size-fhd\" alt=\"\" \/>\t<\/figure>\r\n\t\t<\/div>\r\n\n\n<div class=\"plmb plmb-text mce-content clearfix format-classic\">\r\n\t<p data-path-to-node=\"10\">These findings strongly reinforce the clinical value of the Prosigna test and its \u2264 60 threshold to identify patients unlikely to benefit from chemotherapy. Sparing individuals from unnecessary toxicity significantly improves health trajectories, quality of life, and overall patient-reported outcomes.<\/p>\n<p data-path-to-node=\"11\">Looking ahead, OPTIMA also highlights the urgent need for further research in premenopausal patients. To build a definitive, confident strategy for younger women, data from OPTIMA will be combined with global efforts including the OPTIMA premenopausal extension, Europe's OPTIMA-YOUNG trial, and the US-based OFSET trial.<\/p>\n<p data-path-to-node=\"12\">Congratulations to the entire OPTIMA team on this monumental achievement. We are deeply grateful to continue this vital effort with you, alongside all the dedicated partners, investigators, and institutions associated with our international consortium. Let\u2019s bring this innovation to all premenopausal patients.<\/p>\n<\/div>\r\n\n\n<div class=\"plmb plmb-cta plmb-cta-center\">\r\n\t\r\n\t<div class=\"cta-wrapper\">\r\n\t\t\t\t<a class=\"cta default\" href=\"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2026.44.16_suppl.500\" target=\"_blank\">\r\n\t\t\tRead the article of The Guardian\t\t<\/a>\r\n\t\t\t\t\t<\/div>\r\n<\/div>\r\n","protected":false},"excerpt":{"rendered":"<p data-path-to-node=\"7\">Important results from the OPTIMA study (\u201cOptimal Personalised Treatment of early breast cancer using Multi-parameter Analysis\u201d) were presented at ASCO this weekend by Dr. Robert C. Stein. This UCL-sponsored Phase III trial marks a significant milestone in moving towards...<\/p>\n","protected":false},"author":6,"featured_media":1754,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_uag_custom_page_level_css":"","_analytify_skip_tracking":false,"footnotes":""},"categories":[14],"tags":[],"class_list":["post-2511","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Groundbreaking OPTIMA Study Results Shared at ASCO: Personalising Early Breast Cancer Treatment to Avoid Unnecessary Chemotherapy - Path-for-young<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/path-for-young.unicancer.fr\/es-ar\/groundbreaking-optima-study-results-shared-at-asco-personalising-early-breast-cancer-treatment-to-avoid-unnecessary-chemotherapy\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Groundbreaking OPTIMA Study Results Shared at ASCO: Personalising Early Breast Cancer Treatment to Avoid Unnecessary Chemotherapy - Path-for-young\" \/>\n<meta property=\"og:description\" content=\"Important results from the OPTIMA study (\u201cOptimal Personalised Treatment of early breast cancer using Multi-parameter Analysis\u201d) were presented at ASCO this weekend by Dr. Robert C. Stein. This UCL-sponsored Phase III trial marks a significant milestone in moving towards...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/path-for-young.unicancer.fr\/es-ar\/groundbreaking-optima-study-results-shared-at-asco-personalising-early-breast-cancer-treatment-to-avoid-unnecessary-chemotherapy\/\" \/>\n<meta property=\"og:site_name\" content=\"Path-for-young\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-11T15:06:30+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-11T15:24:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/path-for-young.unicancer.fr\/wp-content\/uploads\/2025\/06\/Optima@2x.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"380\" \/>\n\t<meta property=\"og:image:height\" content=\"185\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"M\u00e9riadec Gaignard\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"M\u00e9riadec Gaignard\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minuto\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/path-for-young.unicancer.fr\\\/es-ar\\\/groundbreaking-optima-study-results-shared-at-asco-personalising-early-breast-cancer-treatment-to-avoid-unnecessary-chemotherapy\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/path-for-young.unicancer.fr\\\/es-ar\\\/groundbreaking-optima-study-results-shared-at-asco-personalising-early-breast-cancer-treatment-to-avoid-unnecessary-chemotherapy\\\/\"},\"author\":{\"name\":\"M\u00e9riadec Gaignard\",\"@id\":\"https:\\\/\\\/path-for-young.unicancer.fr\\\/es-ar\\\/#\\\/schema\\\/person\\\/0b9c691e81c478b95c2b298ef3d3e2c3\"},\"headline\":\"Groundbreaking OPTIMA Study Results Shared at ASCO: Personalising Early Breast Cancer Treatment to Avoid Unnecessary Chemotherapy\",\"datePublished\":\"2026-06-11T15:06:30+00:00\",\"dateModified\":\"2026-07-11T15:24:58+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/path-for-young.unicancer.fr\\\/es-ar\\\/groundbreaking-optima-study-results-shared-at-asco-personalising-early-breast-cancer-treatment-to-avoid-unnecessary-chemotherapy\\\/\"},\"wordCount\":16,\"image\":{\"@id\":\"https:\\\/\\\/path-for-young.unicancer.fr\\\/es-ar\\\/groundbreaking-optima-study-results-shared-at-asco-personalising-early-breast-cancer-treatment-to-avoid-unnecessary-chemotherapy\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/path-for-young.unicancer.fr\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/Optima@2x.jpg\",\"articleSection\":[\"News\"],\"inLanguage\":\"es-AR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/path-for-young.unicancer.fr\\\/es-ar\\\/groundbreaking-optima-study-results-shared-at-asco-personalising-early-breast-cancer-treatment-to-avoid-unnecessary-chemotherapy\\\/\",\"url\":\"https:\\\/\\\/path-for-young.unicancer.fr\\\/es-ar\\\/groundbreaking-optima-study-results-shared-at-asco-personalising-early-breast-cancer-treatment-to-avoid-unnecessary-chemotherapy\\\/\",\"name\":\"Groundbreaking OPTIMA Study Results Shared at ASCO: Personalising Early Breast Cancer Treatment to Avoid Unnecessary Chemotherapy - Path-for-young\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/path-for-young.unicancer.fr\\\/es-ar\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/path-for-young.unicancer.fr\\\/es-ar\\\/groundbreaking-optima-study-results-shared-at-asco-personalising-early-breast-cancer-treatment-to-avoid-unnecessary-chemotherapy\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/path-for-young.unicancer.fr\\\/es-ar\\\/groundbreaking-optima-study-results-shared-at-asco-personalising-early-breast-cancer-treatment-to-avoid-unnecessary-chemotherapy\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/path-for-young.unicancer.fr\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/Optima@2x.jpg\",\"datePublished\":\"2026-06-11T15:06:30+00:00\",\"dateModified\":\"2026-07-11T15:24:58+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/path-for-young.unicancer.fr\\\/es-ar\\\/#\\\/schema\\\/person\\\/0b9c691e81c478b95c2b298ef3d3e2c3\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/path-for-young.unicancer.fr\\\/es-ar\\\/groundbreaking-optima-study-results-shared-at-asco-personalising-early-breast-cancer-treatment-to-avoid-unnecessary-chemotherapy\\\/#breadcrumb\"},\"inLanguage\":\"es-AR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/path-for-young.unicancer.fr\\\/es-ar\\\/groundbreaking-optima-study-results-shared-at-asco-personalising-early-breast-cancer-treatment-to-avoid-unnecessary-chemotherapy\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es-AR\",\"@id\":\"https:\\\/\\\/path-for-young.unicancer.fr\\\/es-ar\\\/groundbreaking-optima-study-results-shared-at-asco-personalising-early-breast-cancer-treatment-to-avoid-unnecessary-chemotherapy\\\/#primaryimage\",\"url\":\"https:\\\/\\\/path-for-young.unicancer.fr\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/Optima@2x.jpg\",\"contentUrl\":\"https:\\\/\\\/path-for-young.unicancer.fr\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/Optima@2x.jpg\",\"width\":380,\"height\":185},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/path-for-young.unicancer.fr\\\/es-ar\\\/groundbreaking-optima-study-results-shared-at-asco-personalising-early-breast-cancer-treatment-to-avoid-unnecessary-chemotherapy\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/path-for-young.unicancer.fr\\\/es-ar\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Groundbreaking OPTIMA Study Results Shared at ASCO: Personalising Early Breast Cancer Treatment to Avoid Unnecessary Chemotherapy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/path-for-young.unicancer.fr\\\/es-ar\\\/#website\",\"url\":\"https:\\\/\\\/path-for-young.unicancer.fr\\\/es-ar\\\/\",\"name\":\"Path for Young\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/path-for-young.unicancer.fr\\\/es-ar\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es-AR\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/path-for-young.unicancer.fr\\\/es-ar\\\/#\\\/schema\\\/person\\\/0b9c691e81c478b95c2b298ef3d3e2c3\",\"name\":\"M\u00e9riadec Gaignard\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es-AR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/c833cc299e91b3604e9ab55006085a8daccdcf877ddfaab1b412770debc32730?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/c833cc299e91b3604e9ab55006085a8daccdcf877ddfaab1b412770debc32730?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/c833cc299e91b3604e9ab55006085a8daccdcf877ddfaab1b412770debc32730?s=96&d=mm&r=g\",\"caption\":\"M\u00e9riadec Gaignard\"},\"url\":\"https:\\\/\\\/path-for-young.unicancer.fr\\\/es-ar\\\/author\\\/meriadec-gaignardstetoo-com\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Groundbreaking OPTIMA Study Results Shared at ASCO: Personalising Early Breast Cancer Treatment to Avoid Unnecessary Chemotherapy - Path-for-young","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/path-for-young.unicancer.fr\/es-ar\/groundbreaking-optima-study-results-shared-at-asco-personalising-early-breast-cancer-treatment-to-avoid-unnecessary-chemotherapy\/","og_locale":"es_ES","og_type":"article","og_title":"Groundbreaking OPTIMA Study Results Shared at ASCO: Personalising Early Breast Cancer Treatment to Avoid Unnecessary Chemotherapy - Path-for-young","og_description":"Important results from the OPTIMA study (\u201cOptimal Personalised Treatment of early breast cancer using Multi-parameter Analysis\u201d) were presented at ASCO this weekend by Dr. Robert C. Stein. This UCL-sponsored Phase III trial marks a significant milestone in moving towards...","og_url":"https:\/\/path-for-young.unicancer.fr\/es-ar\/groundbreaking-optima-study-results-shared-at-asco-personalising-early-breast-cancer-treatment-to-avoid-unnecessary-chemotherapy\/","og_site_name":"Path-for-young","article_published_time":"2026-06-11T15:06:30+00:00","article_modified_time":"2026-07-11T15:24:58+00:00","og_image":[{"width":380,"height":185,"url":"https:\/\/path-for-young.unicancer.fr\/wp-content\/uploads\/2025\/06\/Optima@2x.jpg","type":"image\/jpeg"}],"author":"M\u00e9riadec Gaignard","twitter_card":"summary_large_image","twitter_misc":{"Escrito por":"M\u00e9riadec Gaignard","Tiempo de lectura":"1 minuto"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/path-for-young.unicancer.fr\/es-ar\/groundbreaking-optima-study-results-shared-at-asco-personalising-early-breast-cancer-treatment-to-avoid-unnecessary-chemotherapy\/#article","isPartOf":{"@id":"https:\/\/path-for-young.unicancer.fr\/es-ar\/groundbreaking-optima-study-results-shared-at-asco-personalising-early-breast-cancer-treatment-to-avoid-unnecessary-chemotherapy\/"},"author":{"name":"M\u00e9riadec Gaignard","@id":"https:\/\/path-for-young.unicancer.fr\/es-ar\/#\/schema\/person\/0b9c691e81c478b95c2b298ef3d3e2c3"},"headline":"Groundbreaking OPTIMA Study Results Shared at ASCO: Personalising Early Breast Cancer Treatment to Avoid Unnecessary Chemotherapy","datePublished":"2026-06-11T15:06:30+00:00","dateModified":"2026-07-11T15:24:58+00:00","mainEntityOfPage":{"@id":"https:\/\/path-for-young.unicancer.fr\/es-ar\/groundbreaking-optima-study-results-shared-at-asco-personalising-early-breast-cancer-treatment-to-avoid-unnecessary-chemotherapy\/"},"wordCount":16,"image":{"@id":"https:\/\/path-for-young.unicancer.fr\/es-ar\/groundbreaking-optima-study-results-shared-at-asco-personalising-early-breast-cancer-treatment-to-avoid-unnecessary-chemotherapy\/#primaryimage"},"thumbnailUrl":"https:\/\/path-for-young.unicancer.fr\/wp-content\/uploads\/2025\/06\/Optima@2x.jpg","articleSection":["News"],"inLanguage":"es-AR"},{"@type":"WebPage","@id":"https:\/\/path-for-young.unicancer.fr\/es-ar\/groundbreaking-optima-study-results-shared-at-asco-personalising-early-breast-cancer-treatment-to-avoid-unnecessary-chemotherapy\/","url":"https:\/\/path-for-young.unicancer.fr\/es-ar\/groundbreaking-optima-study-results-shared-at-asco-personalising-early-breast-cancer-treatment-to-avoid-unnecessary-chemotherapy\/","name":"Groundbreaking OPTIMA Study Results Shared at ASCO: Personalising Early Breast Cancer Treatment to Avoid Unnecessary Chemotherapy - Path-for-young","isPartOf":{"@id":"https:\/\/path-for-young.unicancer.fr\/es-ar\/#website"},"primaryImageOfPage":{"@id":"https:\/\/path-for-young.unicancer.fr\/es-ar\/groundbreaking-optima-study-results-shared-at-asco-personalising-early-breast-cancer-treatment-to-avoid-unnecessary-chemotherapy\/#primaryimage"},"image":{"@id":"https:\/\/path-for-young.unicancer.fr\/es-ar\/groundbreaking-optima-study-results-shared-at-asco-personalising-early-breast-cancer-treatment-to-avoid-unnecessary-chemotherapy\/#primaryimage"},"thumbnailUrl":"https:\/\/path-for-young.unicancer.fr\/wp-content\/uploads\/2025\/06\/Optima@2x.jpg","datePublished":"2026-06-11T15:06:30+00:00","dateModified":"2026-07-11T15:24:58+00:00","author":{"@id":"https:\/\/path-for-young.unicancer.fr\/es-ar\/#\/schema\/person\/0b9c691e81c478b95c2b298ef3d3e2c3"},"breadcrumb":{"@id":"https:\/\/path-for-young.unicancer.fr\/es-ar\/groundbreaking-optima-study-results-shared-at-asco-personalising-early-breast-cancer-treatment-to-avoid-unnecessary-chemotherapy\/#breadcrumb"},"inLanguage":"es-AR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/path-for-young.unicancer.fr\/es-ar\/groundbreaking-optima-study-results-shared-at-asco-personalising-early-breast-cancer-treatment-to-avoid-unnecessary-chemotherapy\/"]}]},{"@type":"ImageObject","inLanguage":"es-AR","@id":"https:\/\/path-for-young.unicancer.fr\/es-ar\/groundbreaking-optima-study-results-shared-at-asco-personalising-early-breast-cancer-treatment-to-avoid-unnecessary-chemotherapy\/#primaryimage","url":"https:\/\/path-for-young.unicancer.fr\/wp-content\/uploads\/2025\/06\/Optima@2x.jpg","contentUrl":"https:\/\/path-for-young.unicancer.fr\/wp-content\/uploads\/2025\/06\/Optima@2x.jpg","width":380,"height":185},{"@type":"BreadcrumbList","@id":"https:\/\/path-for-young.unicancer.fr\/es-ar\/groundbreaking-optima-study-results-shared-at-asco-personalising-early-breast-cancer-treatment-to-avoid-unnecessary-chemotherapy\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/path-for-young.unicancer.fr\/es-ar\/"},{"@type":"ListItem","position":2,"name":"Groundbreaking OPTIMA Study Results Shared at ASCO: Personalising Early Breast Cancer Treatment to Avoid Unnecessary Chemotherapy"}]},{"@type":"WebSite","@id":"https:\/\/path-for-young.unicancer.fr\/es-ar\/#website","url":"https:\/\/path-for-young.unicancer.fr\/es-ar\/","name":"Path for Young","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/path-for-young.unicancer.fr\/es-ar\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es-AR"},{"@type":"Person","@id":"https:\/\/path-for-young.unicancer.fr\/es-ar\/#\/schema\/person\/0b9c691e81c478b95c2b298ef3d3e2c3","name":"M\u00e9riadec Gaignard","image":{"@type":"ImageObject","inLanguage":"es-AR","@id":"https:\/\/secure.gravatar.com\/avatar\/c833cc299e91b3604e9ab55006085a8daccdcf877ddfaab1b412770debc32730?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/c833cc299e91b3604e9ab55006085a8daccdcf877ddfaab1b412770debc32730?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/c833cc299e91b3604e9ab55006085a8daccdcf877ddfaab1b412770debc32730?s=96&d=mm&r=g","caption":"M\u00e9riadec Gaignard"},"url":"https:\/\/path-for-young.unicancer.fr\/es-ar\/author\/meriadec-gaignardstetoo-com\/"}]}},"uagb_featured_image_src":{"full":["https:\/\/path-for-young.unicancer.fr\/wp-content\/uploads\/2025\/06\/Optima@2x.jpg",380,185,false],"thumbnail":["https:\/\/path-for-young.unicancer.fr\/wp-content\/uploads\/2025\/06\/Optima@2x-150x150.jpg",150,150,true],"medium":["https:\/\/path-for-young.unicancer.fr\/wp-content\/uploads\/2025\/06\/Optima@2x-300x146.jpg",300,146,true],"medium_large":["https:\/\/path-for-young.unicancer.fr\/wp-content\/uploads\/2025\/06\/Optima@2x.jpg",380,185,false],"large":["https:\/\/path-for-young.unicancer.fr\/wp-content\/uploads\/2025\/06\/Optima@2x.jpg",380,185,false],"1536x1536":["https:\/\/path-for-young.unicancer.fr\/wp-content\/uploads\/2025\/06\/Optima@2x.jpg",380,185,false],"2048x2048":["https:\/\/path-for-young.unicancer.fr\/wp-content\/uploads\/2025\/06\/Optima@2x.jpg",380,185,false],"post-thumbnail":["https:\/\/path-for-young.unicancer.fr\/wp-content\/uploads\/2025\/06\/Optima@2x.jpg",380,185,false],"fhd":["https:\/\/path-for-young.unicancer.fr\/wp-content\/uploads\/2025\/06\/Optima@2x.jpg",380,185,false],"wqhd":["https:\/\/path-for-young.unicancer.fr\/wp-content\/uploads\/2025\/06\/Optima@2x.jpg",380,185,false]},"uagb_author_info":{"display_name":"M\u00e9riadec Gaignard","author_link":"https:\/\/path-for-young.unicancer.fr\/es-ar\/author\/meriadec-gaignardstetoo-com\/"},"uagb_comment_info":0,"uagb_excerpt":"Important results from the OPTIMA study (\u201cOptimal Personalised Treatment of early breast cancer using Multi-parameter Analysis\u201d) were presented at ASCO this weekend by Dr. Robert C. Stein. This UCL-sponsored Phase III trial marks a significant milestone in moving towards...","_links":{"self":[{"href":"https:\/\/path-for-young.unicancer.fr\/es-ar\/wp-json\/wp\/v2\/posts\/2511","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/path-for-young.unicancer.fr\/es-ar\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/path-for-young.unicancer.fr\/es-ar\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/path-for-young.unicancer.fr\/es-ar\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/path-for-young.unicancer.fr\/es-ar\/wp-json\/wp\/v2\/comments?post=2511"}],"version-history":[{"count":3,"href":"https:\/\/path-for-young.unicancer.fr\/es-ar\/wp-json\/wp\/v2\/posts\/2511\/revisions"}],"predecessor-version":[{"id":2516,"href":"https:\/\/path-for-young.unicancer.fr\/es-ar\/wp-json\/wp\/v2\/posts\/2511\/revisions\/2516"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/path-for-young.unicancer.fr\/es-ar\/wp-json\/wp\/v2\/media\/1754"}],"wp:attachment":[{"href":"https:\/\/path-for-young.unicancer.fr\/es-ar\/wp-json\/wp\/v2\/media?parent=2511"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/path-for-young.unicancer.fr\/es-ar\/wp-json\/wp\/v2\/categories?post=2511"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/path-for-young.unicancer.fr\/es-ar\/wp-json\/wp\/v2\/tags?post=2511"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}